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C BY-NC-Abstract Cyclization of various different alkoxy [1-[2-(alkoxy)phenyl]-5-(furan-2-yl)-prop-2-en-
1-one] chalcone with thiosemicarbazide in the presence of NaOH in ethanol afforded a series of
novel 1-N-substituted cyclized pyrazoline analogues [5-(furan-2-yl)-3-[2-(alkoxy) phenyl]-4,5-dihy-
dro-1H-pyrazole-1-carbothioamide 2a–2d. The structures of these compounds were elucidated by
IR, 1H NMR, 13C NMR, Fab mass spectrometry and their purities were conﬁrmed by elemental
analyses. In vitro antibacterial activity of these compounds were evaluated by the disk diffusion
assay and then the minimum inhibitory concentration (MIC) strain of two Gram-positive
and two Gram-negative bacteria like Aeromonas hydrophila, Yersinia enterocolitica, Listeria
monocytogenes, and Staphylococcus aureus, among all the compounds, alkoxy [5-(furan-2-yl)-2-
(benzyloxy)phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide 2b and 5-(furan-2-yl)-1-[2-(naph-
thalen-2-ylmethoxy) phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide 2d showed the most
promising antibacterial agent when compared to gentamicin and tetracycline.
ª 2011 King Saud University. Production and hosting by Elsevier B.V.1675 264235; mobile: +91
com (M. Rani).
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The magnitude of human morbidity is associated with water-
borne diseases like gastroenteritis, caused by emerging patho-
gens Aeromonas hydrophila, Yersinia enterocolitica, and Listeria
monocytogenes, Staphylococcus aureus, which is one of the
major threats to public health in much of the developing world.
Resistance to b-lactam antibiotics is due to the production
of multiple inducible, chromosomally encoded b-lactams
(Gonˇi-Urriza et al., 2000). One million annual cases of enteric
disease, and more than 1.5 million children worldwide are in-
fected and up to 120,000 die every year due to diarrhea alone.
These infections cause loss of productivity and incurmedical ex-
penses (Kvenberg and Archer, 1987). Five-membered heterocy-
clic compounds natural as well as synthetic are important for
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ucts that mimic natural products with biological activity are
heterocyclic in nature (Bart et al., 2002). The cyclization of chal-
cones have provided important applications as potent agents
for the agriculturists in the form of veterinary medicines and
insecticides (Alig et al., 1999) and compounds with pyrazole
ring represent a group of compounds possessing a wide
spectrum of biological activity which exhibit a strong level of
pharmacological effects like antifungal, hypoglycemic, antihy-
pertensive (Zitouni et al., 2000), antipyretic, anti-inﬂammatory
(Bruno et al., 1993) and analgesic properties (Jones et al., 1965;
Goswami et al., 1984; Holla et al., 1987; Abdon et al., 1990;
Mishra et al., 1991). These compounds are also associated to
some more signiﬁcant biological behaviors, namely tranquil-
lizer (Bhat et al., 1967) and antiulcer (Zsolnai, 1962a,b) activi-
ties. On the basis of pharmacological signiﬁcance, scientiﬁc
literature also states that some molecules in the presence of
the pyrazole ring exhibit activities like antiviral (Galabov
et al., 1980), antibacterial (Hazzaa et al., 1983; Rollas et al.,
1991), antitubercular, antiamoebic (Detsi et al., 2009; Solankee
et al., 2010) and anti-cancer (Fathalla et al., 2003). These obser-
vations prompted us to synthesize some new chemical entities
incorporating the active pharmacophores in a single molecular
frame work and to evaluate their biological activities. In this pa-
per we have synthesized pyrazolines by the reaction of various
alkoxy chalcones 1a–1d with thiosemicarbazide in the presence
of NaOH in ethanol (Cowley et al., 2004). The activities of these
compounds were screened in vitro against bacterial strains. The
ongoing research in our laboratory showed that pyrazoline
derivatives are good candidates for these studies. On the basis
of their activity, these compounds were identiﬁed as viable leads
for further studies.2. Experimental
2.1. Materials and reagents
The entire chemicals were purchased from Aldrich Chemical
Company (USA) and were used without further puriﬁcation.
The reactions were monitored by percolated aluminum silica
gel 60F 254 thin layer plates procured from Merck (Germany).
All melting points were measured with a capillary apparatus
which are uncorrected. All the compounds were routinely
checked by IR, 1H NMR, 13C NMR, mass spectrometry and
elemental analyses. IR spectra were recorded in KBr on a Per-
kin–Elmer model 1620 FTIR spectrophotometer. 1H and 13C
NMR spectra were recorded at an ambient temperature using
a Bruker spectrospin DPX-400 MHz spectrophotometer in
CDCl3 and DMSO. The following abbreviations were used
to indicate the peak multiplicity s – singlet, d – doublet, t –
triplet, m – multiplet. FAB mass spectra were recorded on a
JEOL SX102 mass spectrometer using Argon/Xenon (6 kV,
10 mB) gas. Column chromatography was performed on silica
gel (Merck). Anhydrous sodium sulfate was used as a drying
agent for the organic phase.
2.2. Synthesis of (2E)-l-(2-hydroxyphenyl)-3-(furan-2-yl)
prop-2-en-1-one (a): a general method
A suspension of O-hydroxy acetophenone (1 equiv) and furfur-
aldehyde (1 equiv) in ethanolic solution of NaOH (30%) wasstirred for 8 h at room temperature. After the completion of
reaction, the reaction mixture was poured into acidic ice water
pH 2 (adjusted by HCL) to produce a solid compound which
was ﬁltered under suction and washed with H2O. The solid was
ﬁltered recrystallized from CH3OH/CHCl3 (3:1) to obtain pure
chalcone 1 (Husain et al., 2008).
Yellow needles; yield: 95%; m.p. 84 C. Anal. Calc. for
C13H10O3: C, 72.89; H, 4.67. Found: C, 72.85; H, 4.64. IR
(KBr) mmax (cm
1): 1634 (C‚O), 3294 (OH); 1H NMR
(400 MHz, CDCl3): d/ppm: 12.7 (1H, s, –OH), 8.02 (1H, d,
Jtrans = 15.1 Hz, H-3), 7.7 (1H, d, Jtrans = 15.1 Hz, H-2),
7.34 (1H, dd, Jp,m,o = 1.6, 3.5, 8.1 Hz, Ar-H), 7.25 (1H, m,
Ar-H), 7.13 (1H, m, Ar-H), 7.02 (1H, dd, J= 3.5 Hz, Ar-H),
7.3 (1H, t, Ar-H), 6.9 (1H, m, Ar-H), 6.7 (1H, t, Ar-H); 13C
NMR (400 MHz, CDCl3): d/ppm: 192.4 (C‚O), 142.6
(C‚C), 137.8 (C‚C), 152.8, 150.7, 148.6, 138.2, 136.2,
129.4, 128.7, 127.3, 125.5, 123.4 (Ar-C); GC–MS m/z: 215,
Calc. 214.
2.2.1. Synthesis of (2E)-1-[2-(prop-2-en-1-yloxy) phenyl]-3-
(furan-2-yl) prop-2-en-1-one (1a)
Alkoxy chalcones were synthesized by reacting furan chalcone
(a) with an appropriate alkylating agent (like allylbromide,
benzyl chloride, bromoethylacetate, 1-chloromethylnaptha-
lene) in the presence freshly heated K2CO3 in dry acetone
and tetrabutylammonium iodide as PTC. In the absence of
PTC, reaction occured in 70–80 h and yields of the alkoxychal-
cone were below 40%. Use of PTC in these reactions, not only
decreased the reaction time up to 4–5 h but also improved the
yield of alkoxy chalcones derivatives up to 80–85%. The prod-
ucts were thus obtained by crystallization from methanol
(Khan and Yusuf, 2009a).
Light brown; yield: 85%; m.p. 82 C. Anal. Calc. for
C16H14O3: C, 75.59; H, 5.51. Found: C, 75.56; H, 5.48%; IR
(KBr) mmax (cm
1): 1655 (C‚O), 1598 (CH‚CH); 1H NMR
(400 MHz, CDCl3): d/ppm: 7.62 (1H, dd, Jtrans = 15.4 Hz,
H-3), 7.54 (1H, dd, Jtrans = 15.4 Hz, H-2), 7.01 (2H, m,
Ar-H), 7.45 (1H, dd, Jp,m,o = 0.7, 1.8, 7.5 Hz, Ar-H), 6.51
(IH, m, Ar-H), 6.82 (1H, d, J= 7.5 Hz, Ar-H), 6.4 (1H, d,
J= 5.2 Hz, Ar-H), 6.02 (1H, m, Ar-H), 5.45 (2H, q,
J= 6.7 Hz, –CH2), 5.24 (1H, td, –CH), 4.64 (2H, td, Jvic =
6.2 Hz, –CH2);
13C NMR (400 MHz, CDCl3): d/ppm: 192.2
(C‚O), 154.5, 153.6, 144.6 (C‚C), 141.5 (C‚C), 132.5,
131.4, 130.8 128.8, 126.7, 125.8, 120.8 122.6 (Ar-C), 68.5
(CH2), 62.4 (CH2), 42.3 (CH); MS; m/z (M
+) 255.
2.2.2. (2E)-1-[2-(Benzyloxy) phenyl]-3-(furan-2-yl) prop-2-
en-1-one (1b)
Dark brown; yield: 85%; m.p. 85 C. Anal. Calc. for
C20H16O3: C, 78.94; H, 5.26. Found: C, 78.90; H, 5.23%;
IR (KBr) mmax (cm
1): 1603 (C‚O), 1552 (CH‚CH); 1H
NMR (400 MHz, CDCl3): d/ppm: 7.65 (1H, dd, Jtrans =
15.7 Hz, H-3), 7.44 (4H, m, Ar-H), 7.41 (1H, dd,
Jp,m,o = 0.9 Hz, 1.4 Hz, 7.8 Hz, Ar-H), 7.3 (3H, m, Ar-H),
7.05 (1H, m, Ar-H), 7.03 (2H, m, Ar-H), 6.7 (1H, d,
J= 7.8 Hz, Ar-H), 6.42 (1H, dd, Jtrans = 15.7 Hz, H-2),
5.18 (2H, s, –CH2);
13C NMR (400 MHz, CDCl3): d/ppm:
191.4 (C‚O), 154.1, 153.5, 143.8 (C‚C), 141.3 (C‚C),
132.6, 130.9, 130.0, 129.6, 129.6, 128.1, 127.5, 125.8, 122.7,
122.5, 120.4, 121.2, 121.2, 112.7 (Ar-C), 77.42 (CH2); MS;
m/z (M+) 305.
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1-one (1c)
Light brown; m.p. 87 C; yield: 85%. Anal. Calc. for
C17H16O5: C, 68.00; H, 5.33. Found: C, 67.96; H, 5.30%; IR
(KBr) mmax (cm
1): 2980, 2933 (methylene C–H), 1600, 1754
(C‚O), 1549 (CH‚CH); 1H NMR (400 MHz, CDCl3): d/
ppm: 7.4 (2H, d, J= 7.8 Hz, Ar-H), 7.56 (1H, dd,
Jp,m,o = 0.8 Hz, 1.7 Hz, 7.8 Hz, Ar-H), 7.08 (1H, d, Jtrans =
15.2 Hz, H-3), 7.22 (1H, d, Ar-H), 7.07 (1H, m, Ar-H), 7.02
(1H, m, Ar-H), 6.91 (1H, d, Jtrans = 15.2 Hz, H-2), 6.82 (1H,
m, Ar-H), 4.24 (2H, q, Jvis = 6.9 Hz, –OCH2), 1.34 (3H, t,
Jvic = 7.2 Hz, –CH3), 5.16 (2H, s, –CH2);
13C NMR
(400 MHz, CDCl3): d /ppm: 191.2 (2C‚O), 155.8, 154.2,
143.6 (C‚C), 142.5 (C‚C), 132.5, 131.7, 130.3, 128.5,
126.6, 125.4, 120.2 114.6 (Ar-C), 72.4 (CH2), 68.5 (OCH2),
55.4 (CH3); MS; m/z (M
+) 301.
2.2.4. (2E)-1-[2-(Naphthalen-2-ylmethoxy) phenyl]-3-(furan-
2-yl) prop-2-en-1-one (1d)
Light brown; m.p. 94 C; yield: 88%. Anal. Calc. for
C24H18O3: C, 81.35; H, 5.08. Found: C 81.31; H, 5.04%; IR
(KBr) mmax (cm
1): 1633 (C‚O), 1589 (CH‚CH), 1H NMR
(400 MHz, CDCl3): d/ppm: 8.01 (1H, d, J= 6.8 Hz, Ar-H),
7.91 (1H, t, Jtrans = 15.7 Hz, H-3), 7.80 (1H, d, J= 7.8 Hz,
Ar-H), 7.54 (1H, dd, Ar-H), 7.45 (1H, dd, Jtrans = 15.7 Hz,
H-2), 7.31 (2H, d, Ar-H), 7.24 (4H, m, Ar-H), 7.09 (1H, dd,
Jp,m,o = 0.9, 1.6, 7.8 Hz, Ar-H), 7.05 (2H, m, Ar-H), 6.81
(2H, m, Ar-H), 5.49 (2H, s, –CH2);
13C NMR (400 MHz,
CDCl3): d/ppm: 192.4 (C‚O), 154.7, 153.3, 142.6 (C‚C),
138.7 (C‚C), 142.6, 132.5, 131.4, 130.3, 129.4, 128.8, 128.8,
127.5, 126.6, 126.6, 125.3, 124.5, 122.6, 121.5, 120.4, 118.5,
114.3, 114.3 (Ar-C), 74.04 (CH2); m/z (M
+) 355.
2.3. General procedure for the synthesis of pyrazoline from
thiosemicarbazide (2a–2d)
A mixture of alkoxy chalcone (0.5 g, 0.0015 mol), thiosemicar-
bazide (1.5 g, .0023 mol) and NaOH (0.5 g, 0.002 mol) in dry
ethanol (25 ml) was reﬂuxed for 12 h. The progress of reaction
was monitored by TLC. After the completion of reaction, the
reaction mixture was poured into acidic ice water of pH 2
(adjusted by HCL) was ﬁltered and recrystallized in methanol
to obtain a precipitated solid (Khan and Yusuf, 2009b).
2.3.1. 5-(Furan-2-yl)-3-[2-(allyloxy) phenyl]-4,5-dihydro-1H-
pyrazole-1-carbothioamide (2a)
Light yellow; m.p. 125–128 C, yield 91%. Anal. Calc. for
C17H17N3O2S: C, 62.38; H, 5.19; N, 12.84. Found: C, 62.35;
H, 5.15; N, 12.80%. IR (KBr) mmax (cm
1): 3279 (NH), 2924
(CH), 1598 (C‚N), 1343 (C‚S), 1013 (C–N); 1H NMR
(400 MHz, CDCl3): d/ppm: 8.03 (2H, s, –NH2), 7.52 (2H, m,
Ar-H), 7.35 (2H, d, J= 1.8 Hz, Ar-H), 7.40 (1H, d{dd},
Jp,m,o = 1.2, 7.6 Hz, Ar-H), 6.81 (1H, d, J= 7.8 Hz, Ar-H),
6.25 (1H, m, Ar-H), 6.03 (1H, t{dd}, J= 4.6, 12.1, 17.1 Hz,
–CH), 5.03 (2H, td, Jvic = 1.5, 17.2 Hz, –CH2), 4.50 (2H, td,
Jvic = 1.6, 5.2 Hz, –CH2), 5.41 (1Hx, dd, Jxa = 6.7 Hz,
Jxb = 11.4 Hz), 3.82 (1Ha, dd, Jax = 6.7 Hz, Jab = 16.5 Hz),
3.62 (1Hb, dd, Jbx = 11.4 Hz, Jba = 16.5 Hz); 13C NMR
(400 MHz, CDCl3): d/ppm: 176.9 (C‚S), 156.1 (C‚N),
154.2, 142.2, 135.2, 132.1, 129.2, 129.2, 128.1, 127.2, 125.2,
125.2 (Ar-C), 77.02 (CH2), 72.6 (C-4), 74.5 (CH2), 63.2
(C-5), 53.1 (CH); m/z (M+) 328.2.3.2. 5-(Furan-2-yl)-3-[2-(benzyloxy) phenyl]-4,5-dihydro-
1H-pyrazole-1-carbothioamide (2b)
Light yellow; m.p. 112–115 C, yield 92%. Anal. Calc. for
C21H18N3O2S: C, 67.02; H, 4.78; N, 11.17. Found: C, 67.00;
H, 4.75; N, 11.13%. IR (KBr) mmax (cm
1): 3268 (NH), 2922
(CH), 1578 (C‚N), 1353 (C‚S), 1015 (C–N); 1H NMR
(400 MHz, CDCl3): d/ppm: 8.02 (2H, s, –NH2), 7.08 (1H,
d{dd}, Jp,m,o = 1.0, 1.8, 8.7 Hz, Ar-H), 7.62 (1H, dd,
J= 1.8, 8.7 Hz, Ar-H), 7.14 (5H, m, Ar-H), 7.35 (2H, m,
Ar-H), 7.42 (2H, m Ar-H), 6.82 (1H, d, J= 5.2 Hz, Ar-H),
5.04 (2H, s, –CH2), 5.25 (1Hx, dd, Jxa = 6.8 Hz,
Jxb = 11.8 Hz), 3.52 (1Ha, dd, Jax = 6.8 Hz, Jab = 17.2 Hz),
3.25 (1Hb, dd, Jbx = 11.8 Hz, Jba = 17.2 Hz); 13C NMR
(400 MHz, CDCl3): d/ppm 176.7 (C‚S), 156.2 (C‚N),
154.2, 153.1, 142.2, 134.2, 133.1, 132.2, 130.4, 129.2, 129.2,
128.1, 127.2, 125.2, 123.4, 122.7, 122.7, 116.5, (Ar-C), 72.2
(C-4), 67.1 (CH2), 64.04 (C-5); m/z (M
+) 377.
2.3.3. 5-(Furan-2-yl)-3-[2-(ethyloxy) phenyl]-4,5-dihydro-1H-
pyrazole-1-carbothioamide (2c)
Light yellow; m.p. 135 C; yield: 94%. Anal. Calc. for
C18H19N3O4S: C, 57.90; H, 5.09; N, 11.26. Found: C, 57.86;
H, 5.05; N, 11.22%, IR (KBr) mmax (cm
1): 3406 (NH), 2860,
2850 (methylene C–H), 2763 (CH), 1752 (C‚O), 1601
(C‚N), 1304 (C‚S), 1024 (C–N); 1H NMR (400 MHz,
CDCl3): d/ppm: 8.45 (2H, s, –NH2), 7.25 (1H, d{dd},
Jp,m,o = 0.8 Hz, 1.9 Hz, 7.6 Hz, Ar-H), 7.07 (2H, d,
J= 5.1 Hz, Ar-H), 7.52 (2H, d, J= 5.2 Hz, Ar-H), 6.82
(2H, d, J= 7.8 Hz, Ar-H), 4.55 (2H, s, –CH2), 4.25 (2H, q,
Jvic = 7.2 Hz, –OCH2), 1.32 (3H, t, J= 6.91 Hz, –CH3),
5.23 (1Hx, dd, Jxa = 6.5 Hz, Jxb = 11.2 Hz), 3.61 (1Ha, dd,
Jax = 6.5 Hz, Jab = 17.1 Hz), 3.2 (1Hb, dd, Jbx = 11.2 Hz,
Jba = 17.1 Hz); 13C NMR (400 MHz, CDCl3): d/ppm:
191.7 (C‚O), 177.4 (C‚S), 156.8 (C‚N), 154.8, 153.4,
142.8, 134.2, 132.2, 130.2, 128.4, 127.3, 125.5, 122.4 (Ar-C),
67.7 (OCH2), 74.6 (C-4), 62.2 (C-5), 61.6 (CH2), 55.4 (CH3);
m/z (M+) 374.
2.3.4. 5-(Furan-2-yl)-3-[2-(prop-2-en-1-yloxy) phenyl]-4,5-
dihydro-1H-pyrazole-1-carbothioamide (2d)
Light yellow; m.p. 137 C; yield 92%. Anal. Calc. for
C25H21N3O2S: C, 70.25; H, 4.91; N, 9.83. Found: C, 70.21;
H, 4.87; N, 9.83%, IR (KBr) mmax (cm
1): 3461 (NH), 3132
(CH), 1585 (C‚N), 1348 (C‚S), 1008 (C–N); 1H NMR
(400 MHz, CDCl3): d/ppm: 8.01 (2H, s, NH2), 7.02 (1H,
d{dd}, Jp,m,o = 0.8 Hz, 1.9 Hz, 7.6 Hz, Ar-H), 7.42 (2H, dd,
J= 1.8, 7.4 Hz, Ar-H), 7.52 (2H, d, J= 5.2 Hz, Ar-H), 7.82
(5H, m, Ar-H), 7.25 (3H, d, J= 5.0 Hz, Ar-H), 6.82 (1H, d,
J= 8.5 Hz, Ar-H), 5.25 (2H, s, –CH2), 5.32 (1Hx, dd,
Jxa = 6.4 Hz, Jxb = 11.6 Hz), 3.62 (1Ha, dd, Jax = 6.4 Hz,
Jab = 16.8 Hz), 3.34 (1Hb, dd, Jbx = 11.6 Hz, Jba = 16.8 Hz);
13C NMR (400 MHz, CDCl3): d/ppm: 176.9 (C‚S), 156.1
(C‚N), 154.2, 153.2, 142.2, 141.2, 135.2, 132.1, 130.9, 129.4,
128.8, 128.8, 127.6, 125.3, 124.5, 123.2, 122.6, 122.6, 121.5,
121.5, 114.3, 114.3 (Ar-C), 72.3 (C-4), 67.7 (CH2), 61.6 (C-5);
m/z (M+) 428.
3. Results and discussion
All the four synthesized compounds 2a–2d were screened for
their potential to inhibit emerging pathogens A. hydrophila,
Y. enterocolitica, L. monocytogenes and S. aureus responsible
434 M. Rani et al.for gastroenteritis. The present study describes the synthesis
and antibacterial evaluation of some 5-(furan-2-yl)-3-[2-
(alkoxy)phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide
2a–2d pyrazoline derivatives of 1-[2-(alkoxy) phenyl]-3-
(furan-2-yl) prop-2-en-1-one 1a–1d and development of a
series of new pyrazoline derivatives that were synthesized
in satisfactory yields (62–80%) as illustrated in Scheme 1
and their structures were characterized by spectral data. Se-
lected compounds 2a–2d showed similar results when tested
against A. hydrophila, Y. enterocolitica, L. monocytogenes
and S. aureus. The compounds 2b and 2d showed highest
activity as compared to gentamicin (10 lg) and tetracycline
(30 lg). On the basis of the above observations, modiﬁca-
tion will be done to improve antibacterial activity.
3.1. IR spectral studies
Assignment of selected characteristic IR bands provides signif-
icant indications for the formation of the cyclized pyrazoline
analogues of the thiocarbamoyl 2a–2d. In the starting material
chalcones 1a–1d (C‚O), (OH) and (CH‚CH), functionally
absorbed in the expected region; (C‚O) at 1603–1754 cm1,
(OH) at 3294 cm1 and (CH‚CH) at 1552–1589 cm1, respec-
tively. The compounds 3a–3d showed the intense bands in the
region between 1304 and 353 cm1 due to the m(C‚S) stretch-
ing of the thiocarbamoyl 2a–2d group. The IR spectra of the
compounds showed m(C‚N) stretching at 1578–1601 cm1.
In addition, the absorption bands at 1008–1024 cm1 wereO
H
O
+
OH
O
CH3
EtOH / 
NaOH /
S
CNH2
2a -2d
PTC=Bu 4N
+I-
where  R = -CH=CH 2,  -Ph,   -COO
Δ
(1a,2a ) (1b, 2b) (1
X = -Cl,  Br
3 4
5N
N
Ha
O
Hb
HX O
CH2 R
C=S
NH2
Scheme 1 Schematic diagram indicatinattributed to the m(C–N) stretching vibration, which also con-
ﬁrm the formation of desired pyrazoline compounds. The com-
pounds 2a–2d showed additional sharp bands in the region
3279–3406 cm1 due to m(NH) stretching.
3.2. 1H NMR spectral analysis
The 1H NMR spectra (400 MHz, CDCl3), the
1H NMR of
started material chalcones 1a–1d were the two broad doublets
centered at d7.08–7.91 and d 6.42–7.54 which could be ascribed
to H-3 and H-2 protons, respectively, and coupling value of
15.2–15.7 Hz between theses hydrogens describes the trans
geometry around the C-2 and C-3 double bonds. The down-
ﬁeld resonance of the H-3 as compared to H-2 could be as-
cribed to the electron deﬁcient nature of the b-carbon in the
enone moiety. The major features of this spectrum were the
signals of the pyrazoline 2a–2d ring proton (H-x) and (H-a
and b) which were found in the region at d 5.23–5.41 (1H,
dd, Jxa = 6.4–6.8 Hz, Jxb = 11.2–11.8 Hz) and 3.34–3.82
ppm (1H, dd, Jax = 6.4–6.8 Hz, Jab = 16.5–17.2 Hz), respec-
tively. The doublet of doublet at d 5.23 (H-x) converted the
doublet of doublet at 3.34–3.82 (H-a and b), which clearly de-
scribes the inter-relationship between the H-x, b and a. The
proposed expression 2a–2d which is due to vicinal coupling
with two magnetically non-equivalent geminal proton of adja-
cent carbon atom C5 pyrazoline ring. The –CH2 protons ap-
peared at d 4.55–5.49 ppm in 1a–1d and 2a–2d. The NH
proton of different substituted thiocarbamoyl compoundsNaOH
0 oC / EtOH
K2CO3 / PTC 
NH NH2
O
O
CH2 R
O
1a -1d
Et,
 dry acetone
1
OH
O
O
2
3
3
2
R-CH 2-X /
c, 2c) (1d, 2d)
g the synthesis of compounds 2a–2d.
Synthesis and in-vitro-antibacterial activity of [5-(furan-2-yl)-phenyl]-4,5-carbothioamide-pyrazolines 4352a–2d showed a singlet at 8.01–8.45 ppm. The strong deshiel-
ding of the C5 (H-a and b) protons compared with the C4
(H-x) protons of the pyrazoline ring can be assumed due to
its structure Fig. 1.
Finally, 13C NMR (400 MHz, CDCl3) spectra of all com-
pounds were recorded in DMSO and spectral signals are in
good agreement with the probable structures. The methylene
groups for 1c and 2c were resonating at d 55.4 ppm (CH3)
and d67.7–68.5 (OCH2); the downﬁeld resonance of the former
suggests their placement near an electronegative oxygen atom.
The carbon of –CH2 in all compounds resonates at 62.4–
77.42 ppm and the C4 and C5 carbon of pyrazolines 2a–2d
resonated at 72.2–74.6 and 61.6–64.04 ppm, respectively. The
carbon of (C‚O) and (C‚C) displayed signals at 191.2–
192.4 and 138.7–144.6 ppm in 1a–1d compounds. The com-
pounds 2a–2d showed two signals at 176.7–177.4 ppm and
156.1–156.8 ppm assigned to (C‚S) and (C‚N), respectively.
The signals are due to the aromatic carbons and the carbon at
1-N substituted aliphatic group. The other resonates are
shown at their usual position in Section 2.
3.3. FAB mass analysis
Characteristic peaks were observed in the mass spectra of all
compounds, which followed the similar fragmentation pattern.
The spectrum of compound 2a showed a molecular ion peak
(M+) at m/z 328. The characteristics peaks observed within
the mass spectra of pyrazoline compound are given in Section 2.
It may be concluded that this study describes the general
method for the synthesis of some pyrazolines linked through
the 5-aryl ring under the normal conditions. These results3 4
5N
N
Ha
O
Hb
HX O
CH2 R
C=S
NH2
(A)
Figure 1 Schematic diagram indicating the ring conformation of
compounds 2a–2d.
Table 1 Antibacterial activity of pyrazoline derivatives, positive con
measured by the Halo Zone Test (unit, mm).
Compounds Corresponding eﬀect on microorganisms (
A. hydrophila Y. enteroco
2a 16.5 14.7
2b 21.5 24.4
2c 14.5 15.7
2d 25.3 18.6
Gentamicin 21 –
Tetracycline 13 20
DMSO – –show that the compound 2b and 2d exhibited the highest anti-
bacterial activity and overall compounds show more acti-
vity againstA. hydrophila, Y. enterocolitica, L. monocytogenes,
and S. aureus promising antibacterial activity. Thus the accu-
mulation of the pyrazoline derivatives will enable them to
better antibacterial agents as compared to gentamicin and
tetracycline.
4. In vitro antibacterial activities
The in vitro antimicrobial activity was performed using the
disk diffusion method and the Minimum Inhibitory Concen-
tration (MIC) method. Gentamicin and tetracycline were used
as positive controls. The results of antibacterial activity and
Minimum Inhibitory Concentration (MIC) are summarized
in Tables 1 and 2, respectively.
4.1. Biological activity
Pure cultures A. hydrophila, Y. enterocolitica, L. monocytoge-
nes, and S. aureus were grown in brain heart infusion broth
for sensitivity testing. Mueller Hinton agar (Hi-Media) and
pyrazoline compounds 2a–2d absolutely diluted (concentration
of 40, 30, 20 and 10 lg/mL) were applied as described by Bauer
et al. (1966). The strains were tested against the following anti-
biotics (Hi-Media): gentamicin 10 lg and tetracycline 30 lg.
These were enrichments in BHIB for 6–8 h at 37 C, the cul-
tures were streaked on Mueller Hinton agar plates using a cot-
ton swab. With an antibiotic disc dispenser, the discs were
placed on the agar surface. After 30 min of pre-diffusion time,
the plates were incubated at 37 C for 18–24 h, after incuba-
tion, the diameter of the inhibition zones were measured and
compared to the interpretive chart of performance standards
for antimicrobial disk susceptibility tests (Hi-Media) and clas-
siﬁed as resistant, intermediate or sensitive.
4.2. Disc-diffusion and micro dilution assay
In vitro antibacterial activities of pyrazoline 2a–2d derivatives
were carried out using Gram-positive and Gram-negative bac-
teria utilized in this study consisted ofA. hydrophila, Y. entero-
colitica, L. monocytogenes, and S. aureus by the disc diffusion
method using nutrient broth medium [contained (lg/mL): beef
extract 3 g; peptone 5 g; pH 7.0]. In the disc-diffusion method,
sterile paper discs (0.5 mm) impregnated with compound
dissolved in dimethylsulfoxide (DMSO) at concentration
100 lg/mL were used. Gentamicin and tetracycline were used
as the standard drugs, where as DMSO poured disk was usedtrol (gentamicin and tetracycline) and negative control (DMSO)
unit, mm)
litica L. monocytogenes S. aureus
15.6 17.6
21.3 22.8
18.6 16.8
20.8 24.5
– 17
12 14
– –
Table 2 Minimum inhibition concentration (MIC) of pyrazoline derivatives and standard
drugs (gentamicin and tetracycline) (unit, lg/mL).
Compounds (MIC) corresponding eﬀect on microorganisms (unit, lg/mL)
A. hydrophila Y. enterocolitica L. monocytogenes S. aureus
2a 10 10 10 10
2b 30 30 30 30
2c 40 40 40 40
2d 20 20 20 20
3d 30 30 30 30
Gentamicin 10 10 10 10
Tetracycline 30 30 30 30
436 M. Rani et al.as a negative control. Then, the paper discs impregnated with
the solution of the compounds were tested, placed on the sur-
face of the media inoculated with the microorganism. The
plates were incubated for 18 h at 37 C. After incubation, the
diameters of the inhibition zones were measured. The pyrazo-
line derivatives were further checked by MIC method. The re-
sults are presented in Tables 1 and 2. The in vitro studies result
showed that the compounds 2b and 2d exhibit the highest activ-
ity against A. hydrophila, Y. enterocolitica, L. monocytogenes,
S. aureus among all the pyrazolines when compared to antibi-
otics. The susceptibility of the bacteria to the test compounds
were determined by the formation of an inhibitory zone after
48 h of incubation at 37 C. The molecular structure of these
active compounds showed enhanced activity. The distinct dif-
ferences in the antibacterial property of these compounds fur-
ther justify the purpose of this study. The importance of such
work lies in the possibility that the new compounds might be
more efﬁcacious drugs against bacteria for which a thorough
investigation regarding the structure–activity relationship, tox-
icity and in their biological effects which could be helpful in
designing more potent antibacterial agents for therapeutic use.5. Conclusion
Although the synthesis of thiocarbamoyl is very well known
for its antibacterial activity, this research involves the synthesis
of pyrazoline derivatives 2a–2d of alkoxy chalcones 1a–1d. The
antibacterial activity of these pyrazoline compounds was
examined using culture A. hydrophila, Y. enterocolitica, L.
monocytogenes, S. aureus and results showed that compounds
2b and 2d are better antibacterial agents as compared to
gentamicin and tetracycline.Acknowledgments
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